Clinical trial · Interventional
Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Assessment of the Effectiveness of Local Ablathermy Radio Frequency (RF) Bronchial Tumors Primitive Stage IA Non-surgical Patients. Phase II Multicenter National
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung tumors of non-small cell stage 1A are usually treated surgically but many patients are not operable because of their condition or respiratory problems associated with it. The treatment is then suggested that local radiotherapy is conventionally carried out in split mode for 6 weeks at a dose of 60-65 Gy irradiation mode This exposes the patient to complications, including post-radiation pneumonitis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Non-small Cell Neoplasm of Lung Stage Ia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous radiofrequency ablation (RFA) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiofrequency ablathermy
- description
- Percutaneous radiofrequency ablation (RFA)
- interventionNames
- Procedure: Percutaneous radiofrequency ablation (RFA)
Primary outcomes (1)
- measure
- Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA)
- timeFrame
- one year after percutaneous radiofrequency ablation (RFA)
- description
- local control is defined as the absence of progression of the ablated site. rate is defined as the number of alive patient without local progression divided by the number of patients alive at one year.
Secondary outcomes (3)
- measure
- Local Tumor Control Rate 3 Years After Percutaneous Radiofrequency Ablation (RFA)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : 1. Patients over 18 years 2. Histological diagnosis of non-small cell lung tumor established. 3. Stage 1A tumors (lesions \<= 3 cm, N0) report prepared by PET and CT 4. Surgical treatment of the lesion contrindiqué or refused by the patient, 5. ARF considered technically feasible after discussing the case in a multidisciplinary meeting (RCP) 6. Expectancy greater than 6 months life 7. PET before inclusion (8 weeks maximum before radiofrequency) showing uptake (SUV\> = 2.5) at the lesion to be treated, 8. Signed informed consent, 9. Patient affiliated to a social security scheme. Exclusion criteria : 1. Location of the lesion does not allow achieving ablathermy under satisfactory conditions: lesion contiguous to the major anatomical structures of the mediastinum, hilar location (less than 1 cm from the hilum) 2. Disorder of uncontrolled bleeding (TP \<50% TCA\> 1.5 x control). 3. Abnormal blood count platelets \<90000/mm3 4. Cons-indication to general anesthesia 5. Patient with a cardiac pacemaker if a review indicates treatment against ARF 6. pregnancy 7. Patient included in another clinical study 8. Unable to undergo medical monitoring test for geographical, social or psychological reasons, 9. Private patient freedom and major subject of a measure of legal protection or unable to consent.
References
Publications (1)
- RESULTPalussiere J, Chomy F, Savina M, Deschamps F, Gaubert JY, Renault A, Bonnefoy O, Laurent F, Meunier C, Bellera C, Mathoulin-Pelissier S, de Baere T. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg. 2018 Aug 24;13(1):91. doi: 10.1186/s13019-018-0773-y. PMID 30143031